Emerging Stocks Down Under 24 November 2020: Rhythm Biosciences, Hazer Group, Skyfii
Rhythm Biosciences: A Seriously Better Alternative
In today's edition of Emerging Stocks Down Under, the Melbourne-based Rhythm Biosciences, which is developing a next-generation diagnostic for colorectal cancer, has enjoyed a nice re-rating lately. Back on 6 August, you could buy this stock for just 7.8 cents. By 12 November it had made it to 42 cents. That’s because the data for the diagnostic has looked very good so far, and there’s likely more where that came from.
Also in today's edition, a look at hydrogen and graphite producer the Hazer Group (ASX: HZR) and venue analytics developer SkyFii (ASX: SKF).
Get access to all editions through a 30-day FREE TRIAL. No credit card required and the trial expires automatically.
Click here to read the previous edition of Emerging Stocks Down Under published 17 November 2020